Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-007 (Lumateperone) for Schizophrenia
NCT03817528Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumateperone in schizophrenia, sponsored by New York State Psychiatric Institute. Started Mar 2019; status: terminated.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03817528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817528.